Skip to content

Second Enhanced Control of Hypertension and Thrombectomy Stroke Study

An investigator initiated and conducted, prospective, multicentre, randomised outcome-blinded study of blood pressure lowering in patients with acute ischaemic stroke with successful recanalization after mechanical thrombectomy

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900027785
Enrollment
Unknown
Registered
2019-11-28
Start date
2020-03-01
Completion date
Unknown
Last updated
2019-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic stroke

Interventions

Control:SBP 140-180 mmHg
Intensive BP lowering:SBP < 120 mmHg

Sponsors

The George Institute for Global Health (Australia) Beijing Representative Office
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >=18 years; 2. Diagnosis of AIS with LVO confirmed by brain imaging; 3. Fulfill local criteria for conduct of MT therapy; 4. Achieve successful recanalization (TICI score >=2b) after MT; 5. Provide written informed consent (or approved surrogate); 6. Persistent (2 readings =140 mmHg <3 hours after recanalization.

Exclusion criteria

Exclusion criteria: 1. Unlikely to potentially benefit from therapy (e.g. advanced dementia) or very high likelihood of death within 24 hours post-MT, judged by responsible treating clinician; 2. Other medical illness that interferes with outcome assessments and follow-up (e.g. known significant pre-stroke disability (mRS scores 3-5), advance cancer and renal failure); 3. Definite indication/contraindication to different intensities of BP lowering treatment; 4. Specific contraindications to any of the BP agents to be used (eg, patients who are hypersensitive (allergic) to any of the ingredients); 5. Patients with aortic isthmus stenosis and arteriovenous shunt (exception: patients with haemodynamically inactive dialysis shunt); 6. Lactating woman; 7. Currently participating in another trial which would interfere with outcome assessments.

Design outcomes

Primary

MeasureTime frame
a shift analysis of mRS scores;

Secondary

MeasureTime frame
sICH;Death and disability (mRS 3-6);Death;Disability (mRS 3-5);EQ-5D;

Countries

China

Contacts

Public ContactCraig Anderson

The George Institute for Global Health (Australia) Beijing Representative Office

canderson@georgeinstitute.org.cn+86 010 82800577 ext 557

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026